New England Journal of Medicine· 2015Q1

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò et al.

8,585citations
Q1SCImago
2015year

Short summary

Nivolumab significantly improved overall survival (9.2 vs. 6.0 months) and response rates (20% vs. 9%) compared to docetaxel in patients with advanced squamous NSCLC, with substantially fewer grade 3-4 adverse events (7% vs. 55%).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Oncology

OncologyMedicine